Former Speaker of the House John Boehner made waves across FOX Business News and Forbes when he said he was going "all in" on marijuana at the American Cannabis Summit.
But near as I can tell, we were the only ones watching when his successor, top House Republican Paul Ryan, issued a surprise endorsement of cannabidiol (CBD), a non-intoxicating but medically beneficial compound found in marijuana.
Ryan, who is not up for re-election, had some interesting things to say about the increasingly popular medication...
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Marijuana Reform Is a Rare Bipartisan Bright Spot
"It has been proven to work," Ryan said of CBD, citing that it "helps reduce seizures." He also shared that his mother-in-law used a synthetic version of CBD to alleviate her symptoms while dying of melanoma and ovarian cancer.
While putting his stamp of approval on CBD, Ryan, who will retire early next year, also put in a good word for industrial hemp: "There's a lot of industrial uses for hemp that I understand from talking to Mitch McConnell is a big deal to Kentucky architecture, and we're all in favor of that as well."
Special Rebroadcast: John Boehner just revealed why he's going ALL IN on marijuana... and exactly how ordinary Americans can make a fortune from this hundred-billion-dollar industry. Click here to watch...
These proclamations come at a key time, with Republicans and Democrats of all political stripes co-sponsoring important cannabis and cannabis reform legislation.
For instance, Congressional leaders are currently negotiating differences between the House and Senate versions of the Farm Bill, which discusses different regulations regarding industrial hemp.
If the top Republican in the House is throwing his support behind CBD and hemp, it seems more and more likely that his members will fall in line and accept the Senate's hemp-friendly language.
Of course, Ryan isn't the only congressperson throwing his support behind cannabis.
And he's certainly not the most vocal.
As I mentioned, Ryan's predecessor in the Speaker's chair, John Boehner, is making headlines everywhere for participating in our first-ever national cannabis summit.
The staunch marijuana opponent became a strong advocate, and he's sharing just how his thinking on marijuana evolved.
The summit, which you can see here, totally free of charge, covers everything from marijuana stocks set to soar... to the regulations surrounding legalization and several other cannabis-related topics.
I think everyone who's invested in cannabis, wants to invest in cannabis, or simply wants to know what's going on with an important U.S. industry that's already worth as much as $10.8 billion is going to want to hear what Boehner and the other guest panelists have to say.
And you're going to want to hear it before Election Day tomorrow - and another run-up in cannabis stocks.
Follow Money Morning on Facebook, Twitter, and LinkedIn.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.